Financial Analysis: BioNano Genomics (BNGO) versus Its Peers

Share on StockTwits

BioNano Genomics (NASDAQ: BNGO) is one of 24 publicly-traded companies in the “Analytical instruments” industry, but how does it compare to its peers? We will compare BioNano Genomics to related businesses based on the strength of its dividends, profitability, earnings, risk, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares BioNano Genomics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioNano Genomics N/A N/A N/A
BioNano Genomics Competitors -235.98% -26.73% -12.21%

Insider & Institutional Ownership

11.0% of BioNano Genomics shares are held by institutional investors. Comparatively, 60.9% of shares of all “Analytical instruments” companies are held by institutional investors. 14.3% of shares of all “Analytical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for BioNano Genomics and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNano Genomics 0 0 2 0 3.00
BioNano Genomics Competitors 167 869 1237 64 2.51

BioNano Genomics currently has a consensus target price of $11.50, indicating a potential upside of 176.44%. As a group, “Analytical instruments” companies have a potential upside of 0.40%. Given BioNano Genomics’ stronger consensus rating and higher possible upside, equities analysts plainly believe BioNano Genomics is more favorable than its peers.

Earnings and Valuation

This table compares BioNano Genomics and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BioNano Genomics $12.00 million -$18.50 million -1.59
BioNano Genomics Competitors $1.14 billion $146.65 million 13.46

BioNano Genomics’ peers have higher revenue and earnings than BioNano Genomics. BioNano Genomics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

About BioNano Genomics

Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system comprises an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its instruments and consumables for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in North America, Europe, the Middle East, India, Africa, and the Asia Pacific. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Guaranty Federal Bancshares, Inc.  Given Average Recommendation of “Buy” by Brokerages
Guaranty Federal Bancshares, Inc. Given Average Recommendation of “Buy” by Brokerages
Central Valley Community Bancorp  Expected to Announce Earnings of $0.40 Per Share
Central Valley Community Bancorp Expected to Announce Earnings of $0.40 Per Share
-$1.20 EPS Expected for Catalyst Biosciences Inc  This Quarter
-$1.20 EPS Expected for Catalyst Biosciences Inc This Quarter
Brokerages Set $48.00 Target Price for Lydall, Inc.
Brokerages Set $48.00 Target Price for Lydall, Inc.
First Republic Bank  Earns “Outperform” Rating from Wedbush
First Republic Bank Earns “Outperform” Rating from Wedbush
Littelfuse  Cut to Sell at Zacks Investment Research
Littelfuse Cut to Sell at Zacks Investment Research


 
© 2006-2019 Zolmax.